Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.53 |
| ▸ | ACACA | Q13085 | 8/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.41 |
| ▸ | PDE4A | P27815 | 5/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245922 | 1.00 | ACACB (0.53) | ACACBACACAPDE4DPDE4APDE4B | |
| SCHEMBL29750586 | 0.90 | ACACB (0.45) | ACACBACACAPDE4DPDE4APDE4B | |
| SCHEMBL21816532 | 0.90 | ACACB (0.45) | ACACBACACAPDE4DPDE4APDE4B | |
| SCHEMBL22000680 | 0.89 | ACACA (0.49) | ACACBACACAPDE4DPDE4APDE4B | |
| SCHEMBL21816530 | 0.89 | ACACA (0.49) | ACACBACACAPDE4DPDE4APDE4B | |
| SCHEMBL29750457 | 0.89 | ACACA (0.49) | ACACBACACAPDE4DPDE4APDE4B | |
| SCHEMBL18908167 | 0.89 | ACACB (0.49) | ACACBACACAPDE4DPDE4APDE4B | |
| SCHEMBL18883377 | 0.88 | ACACB (0.42) | ACACBACACAPDE4ASLC6A2SLC6A4 | |
| SCHEMBL21816458 | 0.88 | ACACB (0.44) | ACACBACACAPDE4DPDE4APDE4B | |
| SCHEMBL18908179 | 0.87 | ACACB (0.48) | ACACBACACAPDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110431144-B | Cyano-substituted heteroaryl pyrimidone derivatives, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-11142531-B2 | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-11142531-B2 | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200102322-A1 | CYANO SUBSTITUTED HETEROARYLPYRIMIDINONE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-04-02 | — | — | US | disclosed |
| US-20200102322-A1 | CYANO SUBSTITUTED HETEROARYLPYRIMIDINONE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-04-02 | — | — | US | disclosed |
| CN-110431144-A | The heteroaryl hepyramine analog derivative and its preparation method and application that cyano replaces | ZHEJIANG HISUN PHARM CO LTD | 2019-11-08 | — | — | CN | disclosed |
| US-20190241582-A1 | Triazole ACC inhibitors and uses thereof | Nimbus Apollo, Inc. | 2019-08-08 | — | — | US | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091617-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102322-A1 | CYANO SUBSTITUTED HETEROARYLPYRIMIDINONE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | ACACA, COASY, ACACB | ACACB 3/4885ACACA 1/4885PDE4D 3031/4885 |
| US-20190241582-A1 | Triazole ACC inhibitors and uses thereof | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885PDE4D 2986/4885 |
| US-11142531-B2 | Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof | ACACA, COASY, ACACB | ACACB 3/4885ACACA 1/4885PDE4D 3031/4885 |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885PDE4D 2986/4885 |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885PDE4D 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.